



Financial Tear Sheet

Corporate Profile

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com (<http://www.alkermes.com>).

IR Contacts

Sandy Coombs
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6377
E-mail: Sandra.Coombs@alkermes.com (<mailto:Sandra.Coombs@alkermes.com>)

Eva Stroynowski
Co-Head, Investor Relations
Alkermes, Inc.
Phone: 1 781-609-6823
E-mail: eva.stroynowski@alkermes.com (<mailto:eva.stroynowski@alkermes.com>)

Stock Performance

ALKS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$58.47
Change (%)	0.21 (0.36%)
	▼
Volume	992,352
52 Week Low	\$39.65
Market Cap	\$8,957,048,593
Rolling EPS	-1.32
PE Ratio	N/A
Shares Outstanding	153,190,501
Data as of 06/23/17 4:00 p.m. ET	



Recent Headlines & Events


06/12/17 - 7:00 a.m.
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
(phoenix.zhtml?c=92211&p=iroi-newsArticle&ID=2280211)

06/08/17 - 4:00 p.m.
Alkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference (phoenix.zhtml?c=92211&p=iroi-newsArticle&ID=2279920)

06/08/17 - 7:00 a.m.
Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
(phoenix.zhtml?c=92211&p=iroi-newsArticle&ID=2279766)

There are currently no events scheduled.

Mean Recommendation: 2.4



EPS Trend		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	-0.01	-0.01	0.02
QTR	Sep 17	0.03	0.03	0.01
QTR	Dec 17	0.13	0.13	0.09
QTR	Mar 18	0.11	0.11	0.10
FY	Dec 17	-0.04	-0.04	0.07
FY	Dec 18	0.46	0.47	0.67

SEC Filings

Year Filter

Filing Date	Form
06/13/17	CT ORDER (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lNhtbD9yZXBvPXRlbmsmaXBhZ2U9MTE2NTEzNDkmc3Vic2lkPTU3&ListAll=1)
06/08/17	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lNhtbD9yZXBvPXRlbmsmaXBhZ2U9MTE2NDYxNDEmc3Vic2lkPTU3&ListAll=1)
06/08/17	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lNhtbD9yZXBvPXRlbmsmaXBhZ2U9MTE2NDYxMzMmc3Vic2lkPTU3&ListAll=1)
06/01/17	4 (phoenix.zhtml?c=92211&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lNhtbD9yZXBvPXRlbmsmaXBhZ2U9MTE2MzMyMTgmc3Vic2lkPTU3&ListAll=1)


Corporate Governance

Richard F. Pops	Chairman and Chief Executive Officer
Shane Cooke	President
Kathryn L. Biberstein	Senior Vice President, Chief Legal Officer and Chief Compliance Officer, and Secretary Alkermes plc
Madeline D. Coffin	Vice President, Human Resources
Elliot W. Ehrich, M.D.	Executive Vice President, Research and Development, and Chief Medical Officer
James M. Frates	Senior Vice President and Chief Financial Officer
Georgianna Harris, Ph.D.	Vice President, Regulatory Affairs
Blair C. Jackson	Vice President, Business Development
Michael J. Landine	Senior Vice President, Corporate Development
Mark Namchuk, Ph.D.	Senior Vice President, Research, Pharmaceutical and Nonclinical Development
Peter Norman	Vice President, Government Policy and Affairs
Rebecca J. Peterson	Senior Vice President, Corporate Communications
Gordon G. Pugh	Senior Vice President, Chief Operating Officer and Chief Risk Officer
Srdjan Stankovic, M.D., MSPH	Senior Vice President, Clinical Development & Medical Affairs
Mark Stejbach	Senior Vice President, Chief Commercial Officer

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	0	.00	0.0	0
Mutual Fund	0	.00	0.0	0
Insider *	0	.00	0.0	0

*Insider values reflect direct beneficial ownership.

Powered by  Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed